VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE American: CVM), a Phase 3 cancer immunotherapy biopharmaceutical company, announces today that Geert Kersten, Chief Executive Officer, will present at the following conferences:
- 2018 Disruptive Growth & Healthcare Conference at 4:15 p.m. Eastern Time on Tuesday, May 8, 2018. Mr. Kersten will also participate in the Disruptive Injectables & Oncology Panel at 1:15 p.m. Eastern Time on May 8.
- NYC Oncology Investor Conference 2018 at 12:30 p.m. Eastern Time on Wednesday, May 9, 2018
Mr. Kersten’s presentations will be available in the Investor Relations section of the Company's website at www.cel-sci.com/investor_relations.html.
About The 2018 Disruptive Growth & Healthcare Conference
The 2018 Disruptive Growth & Healthcare Conference sponsored by RHK Capital and ReedSmith offers an opportunity to discover life science companies focusing on unmet medical needs with disruptive technologies and business models.
About The NYC Oncology Investor Conference 2018
The NYC Oncology Investor Conference 2018 hosted by OneMed Forum, and sponsored by the National Foundation for Cancer Research, the International Cancer Impact Fund, Klosters Innovation Partners, Wilson Sonsini Law Firm, Torreya Partners, and Marcum is the leading conference for early-stage private and public cancer investing.
About CEL-SCI Corporation
CEL-SCI is a Phase 3 cancer immunotherapy company. The Phase 3 study is fully enrolled with 928 patients. When it comes to cancer immunotherapy, CEL-SCI believes it is most logical to boost the patient’s immune system while it is still intact in order to have the greatest possible impact on survival. Therefore, CEL-SCI treats patients who are newly diagnosed with head and neck cancer with its lead investigational immunotherapy Multikine (Leukocyte Interleukin, Injection), BEFORE they have received surgery, radiation and/or chemotherapy. This approach is unique. Most other cancer immunotherapies are used only after conventional therapies have been tried and/or failed. Head and neck cancer represents about 6% of all cancers. Multikine has received Orphan Drug designation from the FDA for the treatment of head and neck cancer patients with advanced squamous cell carcinoma. CEL-SCI has received patents for Multikine from the US, Europe, China and Japan.
The Company’s LEAPS technology is being developed as a therapeutic vaccine for rheumatoid arthritis and is supported by grants from the National Institutes of Health. The Company has operations in Vienna, Virginia, and in/near Baltimore, Maryland.